Novo Nordisk and St. Luke’s Philippines Partner for Continuing Diabetes Education

SHARE

Denmark based pharmaceutical firm Novo Nordisk has partnered with St. Luke’s Medical Center in the Philippines to promote diabetes care in the country.

By way of a memorandum of agreement with St. Luke’s Medical Center Global City, Novo Nordisk Pharmaceuticals will provide continuing medical education training and related materials on diabetes and insulin therapy to resident physicians and nurses of St. Lukes.

“Novo Nordisk is honored to partner with one of the Philippines’s leading hospitals in achieving our shared goal of changing diabetes through better patient education and support, enhanced CME for health-care professionals, and improved prevention, care and control of diabetes,” said Jeppe Theisen, general manager of Novo Nordisk.

This partnership is part of the increasing investment of Novo Nordisk in the Philippines and its people together with establishing new offices in Bonifacio Global City and  launches of new insulin products.

Dr. Arturo S. de la Peña, head of Medical Practice Group; and medical director at SLMC Global City looks to the partnership to increase standards nationwide for diabetes care in the Philippines.

“Our partnership with Novo Nordisk demonstrates our commitment to maintain the highest standards of patient care and diabetes management,” said Dr. de la Peña.

st.lukes Novo Nordisk Pharmaceuticals Philippines

According to the agreement, Novo Nordisk will give lectures and hold workshops on diabetes management, insulin administration and patient education.

They will also develop training modules and provide demo kits and insulin pens to doctors and nurses at St. Lukes.

“Through this training program, the endocrine section provides optimal care to diabetes patients by keeping our health-care professionals updated on insulin management,” said Dr. Michael Villa, head of Section of Endocrinology at SLMC Global City.

Along with building partnerships with organizations, Novo Nordisk’s continues investing in the Philippines with the opening of new offices in Bonifacio Global City in Taguig as well as the launch of innovative insulin products in the local market.

Comments

comments


Warning: A non-numeric value encountered in /home/every192/public_html/wp-content/themes/Newsmag/includes/wp_booster/td_block.php on line 352